Data as of Mar 14
| -0.03 / -1.20%|
The 1 analysts offering 12-month price forecasts for BioLine RX Ltd have a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. The median estimate represents a +182.26% increase from the last price of 2.48.
The current consensus among 1 polled investment analysts is to Buy stock in BioLine RX Ltd. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.